United States
# |
Name |
Capital Expenditure |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD -749.00 M
|
Sept. 30, 2024 | USD 34.46 | -1.96% |
|
United States |
|
2 |
USD -637.00 M
|
Sept. 30, 2024 | USD 164.41 | -1.15% |
|
United States |
|
3 |
USD -152.59 M
|
Sept. 30, 2024 | USD 78.14 | -3.73% |
|
United States |
|
4 |
USD -20.20 M
|
Sept. 30, 2024 | USD 8.51 | -1.16% |
|
United States |
|
5 |
USD -16.48 M
|
Sept. 30, 2024 | USD 1.97 | -1.50% |
|
United States |
|
6 |
USD -12.73 M
|
Sept. 30, 2024 | USD 2.32 | -6.45% |
|
United States |
|
7 |
USD -6.88 M
|
Sept. 30, 2024 | USD 16.32 | -1.03% |
|
United States |
|
8 |
USD -6.43 M
|
Sept. 30, 2024 | USD 10.23 | -2.76% |
|
United States |
|
9 |
USD -6.40 M
|
Sept. 30, 2024 | USD 9.38 | -6.57% |
|
United States |
|
10 |
USD -4.60 M
|
Sept. 30, 2024 | USD 12.48 | NA |
|
United States |
|
11 |
USD -2.38 M
|
June 30, 2024 | USD 16.59 | -4.16% |
|
United States |
|
12 |
USD -1.14 M
|
Sept. 30, 2023 | USD 3.18 | -5.08% |
|
United States |
|
13 |
USD -995.00 K
|
Sept. 30, 2024 | USD 4.69 | -4.29% |
|
United States |
|
14 |
USD -614.00 K
|
Sept. 30, 2024 | USD 1.86 | 4.49% |
|
United States |
|
15 |
USD -200.00 K
|
Sept. 30, 2024 | USD 12.31 | -23.96% |
|
United States |
|
16 |
USD 0.00
|
July 31, 2024 | USD 2.13 | -2.74% |
|
United States |
|
17 |
USD 0.00
|
Sept. 30, 2024 | USD 5.96 | -8.87% |
|
United States |
The Vaccines company in United States with the highest Capital Expenditure is Moderna, Inc. (NasdaqGS: MRNA) at USD -749.00 M.
The Vaccines company in United States with the lowest Capital Expenditure is INmune Bio, Inc. (NasdaqCM: INMB) at USD 0.00.
The top 10 Vaccines companies in United States by Capital Expenditure are Moderna, Inc., Zoetis Inc., Vaxcyte, Inc., Novavax, Inc., HilleVax, Inc., ImmunityBio, Inc., ADMA Biologics, Inc., Vir Biotechnology, Inc., Immunome, Inc. and Dynavax Technologies Corporation.
The bottom 10 Vaccines companies in United States by Capital Expenditure are INmune Bio, Inc., Anixa Biosciences, Inc., Atara Biotherapeutics, Inc., HOOKIPA Pharma Inc., TriSalus Life Sciences, Inc., Arbutus Biopharma Corporation, Arcturus Therapeutics Holdings Inc., Dynavax Technologies Corporation, Immunome, Inc. and Vir Biotechnology, Inc..